H. Lundbeck ASHLUBF 78 Net Margin % is 23.27% as of Mar. 2026, which is 90% above its 10-year median of 12.23. GuruFocus rates HLUBF with a GF Score™ of 78/100 and a GF Value™ of $5.65 (Fairly Valued). The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, H. Lundbeck AS ranks better than 77.38% on this metric.
Net margin is calculated as Net Income divided by its Revenue. H. Lundbeck AS's Net Income for the
three
months ended in Mar. 2026 was $256 Mil. H. Lundbeck AS's Revenue for the
three
months ended in Mar. 2026 was $1,102 Mil. Therefore, H. Lundbeck AS's net margin for the quarter that ended in Mar. 2026 was 23.27%.
The historical rank and industry rank for H. Lundbeck AS's Net Margin % or its related term are showing as below:
HLUBF'
s Net Margin % Range Over the Past 10 Years
Min: 7.75 Med: 12.23 Max: 21.86
Current: 14.49
HLUBF's Net Margin % is ranked better than 77.38% of 955
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs HLUBF: 14.49
H. Lundbeck AS (OTCPK:HLUBF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
H. Lundbeck AS Net Margin % Related Terms
H. Lundbeck AS Net Margin % Historical Data
* Premium members only.
The historical data trend for H. Lundbeck AS's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
H. Lundbeck AS Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's Net Margin % distribution charts can be found below:
* The bar in red indicates where H. Lundbeck AS's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
H. Lundbeck AS (HLUBF) has a Net Margin % of 23.27% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on H. Lundbeck AS and its competitors. This is 90% above median its historical median of 12.23. Over the past decade, H. Lundbeck AS's Net Margin % has ranged from 7.75 to 21.86. According to the industry distribution chart, H. Lundbeck AS ranks #216 out of 955 companies in the Drug Manufacturers industry, placing it in the top 22.6%.
Is H. Lundbeck AS's Net Margin % too high?
H. Lundbeck AS's current Net Margin % of 23.27% is 90% above median its 10-year median of 12.23. Over the past 10 years, this metric has ranged from a low of 7.75 to a high of 21.86. The Drug Manufacturers industry median Net Margin % is 5.69. H. Lundbeck AS's value of 23.27% is 309% above this industry median. Based on the distribution chart, H. Lundbeck AS ranks #216 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, H. Lundbeck AS has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, H. Lundbeck AS ranks #216 out of 955 companies for Net Margin %. This places H. Lundbeck AS in the top 23% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.69. H. Lundbeck AS's value of 23.27% is 309% above this benchmark. Historically, H. Lundbeck AS's own Net Margin % has ranged from 7.75 to 21.86 over the past decade. While the company's 10-year median is 12.23 vs. the industry median of 5.69, H. Lundbeck AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. H. Lundbeck AS's current Net Margin % of 23.27% is 309% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on H. Lundbeck AS and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. H. Lundbeck AS's current Net Margin % is 23.27%, which is 90% above median its own 10-year median of 12.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (HLUBF) is currently considered Fairly Valued. The stock's GF Value™ is $5.65, compared to a current price of $5.50 — trading 2.7% below its estimated fair value. The current Net Margin % is 23.27%, which is 90% above median its 10-year median of 12.23 and 309% above the Drug Manufacturers industry median of 5.69. H. Lundbeck AS's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For H. Lundbeck AS (HLUBF), the current Net Margin % is 23.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is H. Lundbeck AS (HLUBF) Overvalued in 2026?
Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued.
The current stock price of $5.50 is trading 2.7% below its estimated GF Value™ of $5.65.
GuruFocus considers H. Lundbeck AS to be Fairly Valued.
Key valuation signals for HLUBF:
Net Margin %: 23.27% (90% above median its 10-year median of 12.23)
GF Value™: $5.65 vs. price of $5.50 (2.7% below fair value)
Industry Position: 309% above the Drug Manufacturers median (#216 of 955)
No single metric tells the full story. See the HLUBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
78GF Score
Get the complete analysis for HLUBF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HLUBF has been successfully added to your 
